Crossmark

New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach

Published Online: 2022-01-21

Published Print: 2022-01

Authors

Jimenez, Camilo

Xu, Guofan

Varghese, Jeena

Graham, Paul H.

Campbell, Matthew T.

Lu, Yang
License Information

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2022-01-01
More Information

Article History

Accepted: 21 October 2021

First Online: 21 January 2022

Declarations

:

: Camilo Jimenez has received research support from Lantheus Pharmaceuticals, Exelixis, Merck Sharp and Dohme, and Pfizer; Camilo Jimenez is consultant for Lantheus, Merck Sharp and Dohme, Pfizer, and HRA Pharma.Matthew T. Campbell is consultant for AstraZeneca, Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, AXDev, and Pfizer. Matthew T. Campbell has received research support from Apricity Health, Aravive, AstraZeneca, EMD Serono, Exelixis, Janssen, and Pfizer; non-CME education: Bristol Myers Squibb, Merck, Roche, and Pfizer.Yang Lu is consultant for General Electric, Inc.Jeena Varghese, Guofan Xu, and Paul Graham do not have conflict of interest.

Document is current